Pay in 4 interest-free payments of $5.59 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
For mild to moderate cases: 300 mg to 600 mg once a day
The widespread prevalence of obesity necessitates production strategies that can meet the growing demand for anti-obesity medications without increasing the carbon footprint of these processes
According to previous reports by GPCR3D, Retatrutide (LY3437943) is a triple agonist peptide developed by Eli Lilly that targets the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R)
Unlike growth hormone releasing peptides that must be taken away from food, GHK-Cu can be administered regardless of meal timing
US$ 24.93
US$ 22.16
US$ 22.12
US$ 29.59
US$ 29.23
